BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company founded in 1997 that is dedicated to transforming lives through genetic discovery. The company develops and commercializes innovative medicines that target the underlying causes of genetic conditions. With a focus on bold science, BioMarin relentlessly pursues advancements in gene therapy and treatment modalities aimed at addressing serious health challenges. Their strong commitment to breakthroughs in healthcare is seen in their development of eight market-leading products that treat a variety of life-threatening conditions such as achondroplasia and severe hemophilia A. This progress is fueled by BioMarin's unparalleled expertise in genetics and molecular biology.

Headquartered in San Rafael, California, and operating in over 70 countries, BioMarin employs approximately 3,000 people globally. The company's success is driven by a people-first culture where top-tier talent collaborates to deliver solutions that meet the needs of patients and health care providers alike. Their pipeline includes multiple investigational medicines that are vital for patients with genetic disorders, demonstrating BioMarin's ongoing dedication to innovation and patient care. As they look toward the future, BioMarin aims to continue setting the standard in biotechnology through impactful, transformative therapies.